Intermittent ibrutinib in chronic lymphocytic leukemia
This research study is investigating a different way to use a medicine called ibrutinib for people with chronic lymphocytic leukaemia (CLL). Currently, people usually take ibrutinib continuously. This study wants to see if giving ibrutinib in cycles, with planned breaks, could still be effective and perhaps have fewer side effects. This is an early-stage study, meaning it's one of the first times this new approach is being tested in people. The main goals are to make sure it's safe, to understand how the body handles the medicine when given this way, and to see if it helps manage CLL. It's open to adults aged 18 and over, of any gender, who have CLL.
At a glance
What is this study about?
This research is looking into a new way to treat chronic lymphocytic leukaemia (CLL). CLL is a type of cancer that affects specific white blood cells. A common medicine used to treat it is called ibrutinib. Usually, people take ibrutinib every day without stopping. However, sometimes taking medicine continuously can lead to side effects. This study wants to explore if taking breaks from the medicine might be beneficial.
Researchers want to see if patients could take ibrutinib for a certain period, then have a break, and then start taking it again. This is called 'intermittent' dosing. The main idea is to find out if this cycled approach is still effective at controlling CLL and if it might reduce some of the side effects that can come from continuous use.
This is a very early stage of research, sometimes called a 'Phase I' study. This means it's primarily focused on safety. The team will carefully monitor participants to understand how their bodies react to the medicine when given in this new way and to see if there are any unexpected effects. While it's early, understanding if these short breaks are feasible could eventually lead to improved treatment plans for people with CLL, potentially making their lives more comfortable.
Key takeaways
- This study explores taking ibrutinib for CLL with planned breaks.
- It's an early-stage study, focusing on safety and how the body handles the new dosing.
- Potential benefits include fewer side effects while still managing CLL.
- Participants must be 18 or older with CLL.
- Regular hospital visits and blood tests will be part of the study.
- You can stop participating at any time.
Who may be eligible?
To be considered for this study, you must be at least 18 years old. There's no upper age limit, and the study is open to both men and women.
While the detailed eligibility wasn't provided, generally for a study like this, you would need to have been diagnosed with chronic lymphocytic leukaemia (CLL). It's likely that your doctors would also look at your overall health, how well your organs are working, and what other treatments you might have had or are currently having.
It's important to remember that the specific rules about who can join can be quite strict to make sure the study is safe and that results are clear. Your individual medical history would be carefully reviewed by the study team to see if you meet all the necessary requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have chronic lymphocytic leukaemia (CLL)?
- Are you able to travel to study appointments?
- Are you comfortable potentially taking medication in cycles with breaks?
- Have you discussed this type of study with your specialist doctor?
What does participation involve?
If you decide to take part in this study, you will be given the medicine ibrutinib to take. Unusually, this study involves taking the medicine in cycles, meaning you'll take it for a period and then have a planned break, before starting it again. This is the main thing the researchers are testing.
Throughout the study, you would have regular visits to the hospital or clinic. During these visits, you'd likely have blood tests to check your CLL and how your body is reacting to the medicine. Doctors and nurses would also ask you about any side effects you might be experiencing and how you are feeling generally. The total duration of your participation, including how long you take the medicine and how often you'd need to come for appointments, isn't specified but will be clearly explained by the research team.
Potential risks and benefits
Locations (2)
- —UnverifiedSweden
- —UnverifiedNorway
Common questions
What is chronic lymphocytic leukaemia (CLL)?
CLL is a type of cancer that affects certain white blood cells in your body. It usually progresses slowly.
What is ibrutinib?
Ibrutinib is a medicine used to treat CLL and some other blood cancers. It works by blocking a protein that helps cancer cells grow.
What does 'intermittent' treatment mean?
It means you take the medicine for a period, then stop for a planned break, and then start taking it again. It's different from taking it continuously.
Why are doctors looking at a new way to give ibrutinib?
They want to see if taking breaks from the medicine might reduce side effects while still being effective against CLL, potentially making treatment easier for patients.
Will I have to pay to be in the study?
No, you will not have to pay for the study medicine or the extra tests required specifically for the study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.